{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:04:30Z","timestamp":1648731870569},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"DOI":"10.1093\/mmy\/myu042","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T05:38:54Z","timestamp":1405057134000},"page":"728-735","source":"Crossref","is-referenced-by-count":6,"title":["Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice"],"prefix":"10.1093","volume":"52","author":[{"given":"Magali","family":"Bourdelin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Grenouillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Daguindau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Muret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohan","family":"Desbrosses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Dubut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Limat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Larosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,7,10]]},"reference":[{"key":"key\n\t\t\t\t20171012051510_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20142009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171012051510_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2010.11.021","article-title":"A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis","volume":"37","author":"Bryant","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20171012051510_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1439-0507.2010.01979.x","article-title":"Posaconazole prophylaxis in patients with acute myelogenous leukaemia\u2014results from an observational study","volume":"54","author":"Egerer","year":"2011","journal-title":"Mycoses"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20171012051510_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1439-0507.2010.01980.x","article-title":"Clinical experience with posaconazole prophylaxis\u2014a retrospective analysis in a haematological unit","volume":"54","author":"Hahn","year":"2011","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20171012051510_bib5","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1128\/AAC.00815-12","article-title":"Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease","volume":"56","author":"Tonini","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2010.04.017","article-title":"Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients","volume":"17","author":"Winston","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20171012051510_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1658-3876(09)50019-2","article-title":"JACIE accreditation in 2008: demonstrating excellence in stem cell transplantation","volume":"2","author":"Pamphilon","year":"2009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"key\n\t\t\t\t20171012051510_bib8","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1128\/AAC.01178-08","article-title":"Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers","volume":"53","author":"Dodds Ashley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2515\/therapie\/2011010","article-title":"Level of evidence for therapeutic drug monitoring of posaconazole","volume":"66","author":"Lefeuvre","year":"2011","journal-title":"Therapie"},{"key":"key\n\t\t\t\t20171012051510_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jchromb.2007.01.021","article-title":"Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection","volume":"852","author":"Chhun","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"key\n\t\t\t\t20171012051510_bib12","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012051510_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.11665","article-title":"Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology","volume":"94","author":"Cornely","year":"2009","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20171012051510_bib14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20171012051510_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1586\/14787210.3.4.467","article-title":"Posaconazole: clinical pharmacology and potential for management of fungal infections","volume":"3","author":"Groll","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20171012051510_bib16","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012051510_bib18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00277-013-1693-5","article-title":"Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis","volume":"92","author":"Ping","year":"2013","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t20171012051510_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012051510_bib20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00228-012-1212-y","article-title":"Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"68","author":"Vehreschild","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20171012051510_bib21","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/AAC.05937-11","article-title":"Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection","volume":"56","author":"Cornely","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrc1318","article-title":"The pathobiology of mucositis","volume":"4","author":"Sonis","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"key\n\t\t\t\t20171012051510_bib23","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib24","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AAC.00939-09","article-title":"Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults","volume":"53","author":"Lebeaux","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib25","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1128\/AAC.01177-12","article-title":"Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"56","author":"Vaes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib26","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1128\/AAC.01586-13","article-title":"Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations","volume":"57","author":"Cojutti","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib27","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib28","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1111\/j.1439-0507.2011.02020.x","article-title":"Optimising absorption of posaconazole","volume":"54","author":"Green","year":"2012","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20171012051510_bib29","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2012.09.001","article-title":"Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis","volume":"40","author":"Ross","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171012051510_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10096-011-1288-9","article-title":"Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake","volume":"31","author":"Eiden","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171012051510_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20171012051510_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171012051510_bib34","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1128\/AAC.05900-11","article-title":"Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/bmt.2010.185","article-title":"Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation","volume":"46","author":"Sanchez-Ortega","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20171012051510_bib36","first-page":"34","article-title":"A 10-year survey of fungal aerocontamination in hospital corridors: a reliable sentinel to predict fungal exposure risk?","volume-title":"J Hosp Infect","author":"Reboux","year":"2014"},{"key":"key\n\t\t\t\t20171012051510_bib37","first-page":"109","article-title":"Invasive fungal infections in hospital discharge data, metropolitan France, 2001\u20132010","volume":"12\u201313","author":"Bitar","year":"2012","journal-title":"Bull Epidemiol Hebdo"},{"key":"key\n\t\t\t\t20171012051510_bib38","first-page":"LB2966","article-title":"Phase 3 pharmacokinetics and safety study of posaconazole tablet in patients at risk for invasive fungal infection","volume-title":"23rd European Congress of Clinical Microbiology and Infectious Diseases ECCMID, Berlin, Germany, 27\u201330 April 2013","author":"Cornely","year":"2013"},{"key":"key\n\t\t\t\t20171012051510_bib39","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012051510_bib40","first-page":"3610","article-title":"Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease","volume-title":"Antimicrob Agents Chemother","author":"Maertens","year":"2014"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/52\/7\/728\/9349353\/myu042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T09:15:18Z","timestamp":1507799718000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/mmy\/article\/52\/7\/728\/2812285\/Posaconazole-prophylaxis-in-neutropenic-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,10]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,10]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myu042","relation":{},"ISSN":["1460-2709","1369-3786"],"issn-type":[{"value":"1460-2709","type":"electronic"},{"value":"1369-3786","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,10]]},"published":{"date-parts":[[2014,7,10]]}}}